ABCANN GLOBAL CORPORATION (CVE:ABCN) reported that it has retained Dr. Michael Shannon as company’s Chief Medical Consultant. He had been with the Canadian Armed Forces for more than 30 years, and have worked as Deputy Surgeon General for Canada.
Back in 1996, he took duties within Health Canada for re-structuring the Canadian blood system and the advancement of a new corporate entity committed solely to the organization of blood services in Canada. Dr. Shannon was then engaged as Director General for the Lab Centre for Disease Control. In 2000, Dr. Shannon resigned from the roles with Federal Government only to pursue a career in industry.
In that role, he simultaneously led a Phase 3 clinical study in Canada, the U.S. and Great Britain for a simulated blood substitute offering. Dr. Shannon has been engaged in medical bio-oxidative research since 1987 and has worked as the Senior Medical Advisor to famous firm, Medizone International since 2002.
Aaron Keay, the CEO of ABcann, reported that in the future they intend to participate in numerous clinical studies involving distinct modes of delivery and various research assignments with potentially considerable clinical implications so as to support the approval of cannabis treatment by the conventional medical community. Dr. Shannon’s expertise and experience, along with his recognized credibility, will help ABcann through this process as it moves these initiatives forward.
The company’s modular approach to systems know-how removes scale-up risk and enables it to locate anywhere across the globe and maintain quality and consistency of product. It should be noted that ABcann is expanding capacity in its prevailing facility to approximately 30,000 square feet and concurrently undertaking expansion into a 150,000 square feet facility in Napanee. It is even pursuing different opportunities in Australia, Germany and other jurisdictions along with the initiatives focused on exploring the development of numerous delivery vehicles.